Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2015. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of August 31, 2015:
- Total Issued Ordinary Shares: 5,358,151,256 (25p each)
- Treasury Shares: 491,515,950
- Total Voting Rights: 4,866,635,306
No material changes to financial performance or operational strategy are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the calculation of voting rights for shareholder notification purposes under the Financial Conduct Authority's rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,866,635,306) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (491,515,950) as of August 31, 2015.
- Review the Company's Form 20-F for comprehensive financial performance data, as this 6-K does not contain financial statements.